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1. Introduction 
Hepatitis B Virus (HBV) infection is a global health problem: an estimated two billion people 
(one-third of the global population) have been infected with HBV at some point in their life; of 
these, more than 350 million suffer from chronic HBV infection, resulting in over 600,000 
deaths each year, mainly from cirrhosis or liver cancer [1]. More than 10% of the global chronic 
HBV population resides in India [2]; infection may lead to liver damage that results in acute or 
chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) (Figure 1). HBV 
infection was first identified in 1965 when Blumberg and co-workers [3] found the hepatitis B 
surface antigen (HBsAg), originally termed as Australia antigen. Enhanced viral replication 
leading to a vigorous and extensive immune response may lead to massive liver injury 
resulting spontaneously into fulminant hepatic failure. The seriousness of disease incidence is 
mainly related to various host factors (age, gender, duration of infection, immune response) 
and viral factors (viral load, genotype, quasispecies) (Figure 2). Recent evidence shows that 
considerable molecular variation occurs throughout the HBV genome, which is correlated 
with geographical distribution of genotypes and severity of disease. 
 
Figure 1. HBV mediated liver damage among various stages 
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Figure 2. Host – pathogen factors in disease manifestation 
1.1. HBV evolution 
The history and origin of HBV is partially understood. The evolution of HBV can be traced 
from lowest vertebrates such as the birds infecting virus i.e. avian hepadnavirus which 
shares a sequence homology of 40%, non-primate such as rodents infecting wood chuck 
HBV viruses shares 80% homology [4, 5]. However, highest incidence of greater than 94% of 
homology is found to occur in primates infecting viruses suggesting an evolutionary 
sequence for the human HBV [6]. 
 The long time evolution of HBV therefore leads to the occurrence of various genotypes, 
subgenotypes, mutants, recombinants and even quasispecies [7]. Major forces such as 
genetic drift, bottle neck effects, founder effects and recombination played a vital role in 
evolution, adaptation of HBV and become a successful pathogen in the host. The genetic 
variability, in conjunction with the migration of human race, has led to the divergence of 
HBV into genetically different groups, called genotypes, with a distinct geographic 
distribution. Some researchers suggest that HBV co-evolved with modern humans, as they 
migrated from Africa, around 100,000 years ago [8,9]. Based on the prevalence, geographic 
distribution and characteristic of recombinant genotypes, it can be suggested that genotypes A 
and D co-exist over a relatively long period, while genotypes B and C are believed to have 
recent epidemiological contact in Asia [10]. The genetic diversity of HBV and its geographical 
distribution may help us to reconstruct the evolutionary trend of HBV. This may help to 
generate additional genetic data on the evolution and migration pattern of man [8]. 
1.2. Hepatitis B Virus: Molecular virology 
HBV is a hepatotropic, non-cytopathic virus and a prototype member of the family 
Hepadnaviridae with a genome size of ~3,200 base pairs. The viral genome consists of a 
partially double-stranded, relaxed-circular DNA (RC-DNA), comprising a complete coding 
strand (negative strand) and an incomplete non-coding strand (positive strand), which 
replicates by reverse transcription via an RNA intermediate. Due to reduced fidelity of the 
reverse transcription process, this pregenomic RNA (pgRNA) is prone to mutation. The 
genome encodes four overlapping reading frames that are translated to make the viral core 
protein (HBcAg), the surface proteins (HBsAg) , a reverse transcriptase (RT), and the 
hepatitis B “x” antigen (HBxAg).  
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1.3. Viral entry and replication 
HBV has a high degree of species and tissue specificity that results in very high levels of 
viral replication without actually killing the infected cell directly. The mechanism through 
which HBV enters hepatocyte or other susceptible cells remains elusive mostly owing to 
lack of a proper cell culture system. As a pararetrovirus, HBV uses reverse transcription to 
copy its DNA genome and lack of proof-reading capability permits the emergence of mutant 
viral genomes and quasispecies.  
Upon infecting a hepatocyte, the HBV genome is delivered in to the nuclear compartment 
where cellular repair enzymes are involved in repairing the viral genome into covalently 
closed circular DNA (cccDNA). This viral DNA acts as a transcriptional template [11, 12] for 
the generation of the pregenomic mRNA (pg mRNA), pre-core mRNA and all other subviral 
mRNAs [13, 14]. Subsequently, cccDNA is chromatinized into viral minichromosome that 
ultimately serves as an intrahepatic reservoir of HBV and stays throughout the life of the 
chronically infected host [15, 16]. The pregenomic RNA is encapsulated by the virion core 
particle and reversely transcribed by the viral polymerase, forming a single-strand DNA 
(negative strand). Subsequently, the pregenome is degraded and the negative strand DNA 
then acts as a template for synthesis of a positive strand DNA with variable length. Finally, the 
HBV genome is either encapsulated to produce virions to be secreted out, or recycled back to 
the nucleus to maintain a pool of cccDNA, resulting in the formation of a steady-state 
population of 5–50 copies of cccDNA molecules per infected hepatocyte [14, 17] (Figure 3). 
 
Figure 3. Viral entry and replication cycle of HBV 
2. HBV genomic organization and proteins 
The HBV genomes comprise a partially double-stranded 3.2kb DNA molecule, organized 
into 4 overlapping open-reading frames (ORFs). Four sets of mRNAs are then transcribed 
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from the viral minichromosomes using host cell machinery, RNA polymerase II. These 
molecules are then transported by cellular proteins to the cytoplasm where they are 
translated to produce the viral proteins: hepatitis B core antigen (HBcAg or nucleocapsid 
protein from the 3.5 kb RNA); the soluble and secreted hepatitis B e antigen (HBeAg, from 
the 3.5 kb RNA ); the Pol protein (from the 3.5 kb RNA, which is longer than the viral entire 
genome); the viral envelope proteins HBsAg (from the 2.4 and 2.0 kb RNAs) and hepatitis B 
X protein (HBx from the 0.7 kb RNA). The dynamic nature of individual viral proteins and 
insufficient immune response elicited by the infected host immune cells lead to the 
persistence of HBV infection 
 
Figure 4.  
2.1. Hepatitis B virus surface antigen (HBsAg) 
Since Blumberg’s discovery of HBsAg in 1965, it has been used as the hallmark for the 
diagnosis of HBV infection [18]. HBsAg is the prototype serological marker of HBV infection 
that characteristically appears after 1 to 10 weeks of an acute exposure to HBV but before the 
onset of visible symptoms or elevation of serum alanine aminotransferase (ALT) [19]. 
HBsAg circulates in a wide array of particulate forms such as competent virions (42 nm, 
Dane particles), 20 nm diameter filaments of variable length, and 20–22 nm spherical 
defective particles, corresponding to empty viral envelopes. It exceeds virions by a variable 
factor of 102 – 105 and accumulates several hundred micrograms per ml of serum [13]. The 
principal function of the HBs protein as a virological structure is to enclose the viral 
components, in addition to playing a major role in cell membrane attachment to initiate the 
infection process by binding to the hepatocyte plasma membrane [20]. Persistence of HBsAg 
for more than 6 months indicates chronic infection and it is estimated that fewer than 5% of 
immunocompetent adult patients with acute hepatitis B progress to chronic infection [21]. 
The immune response enhancing ability of HBsAg is not clear yet it is understood that large 
amounts of HBsAg may induce T cell anergy, leading to decreased antibody-mediated 
neutralization of HBV and generalized hyporesponsiveness towards pathogens.  
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2.2. Hepatitis B core antigen (HBcAg) 
HBcAg is the major constituent of the nucleocapsid, which is essential for viral replication. It 
also forms a part of ichosahedral subviral particles that packs the viral reverse polymerase 
and the pregenome [22] derived from the ORF-C. It has either 183 or 185 amino acids 
depending on the genotype of the virus. HBcAg is a particulate and multivalent protein 
antigen which can function as both a T cell-independent and a T cell-dependent Ag [23] and 
is ~1000 fold more immunogenic than the HBeAg [24]. The response of T cells to HBcAg has 
been reported to contribute to the resolution and seroconversion in chronic hepatitis B [25].  
2.3. Hepatitis B envelope antigen (HbeAg) 
HBeAg is an accessory protein of HBV, not essential for replication in vivo [26, 27] but 
important for natural infection. This antigen has been used clinically as an index of viral 
replication, infectivity, severity of disease, and response to treatment [28]. HBeAg may play 
a role in perpetuating viral infection during perinatal transmission, often resulting in 
chronic infection and eliciting HBe/HBcAg-specific T helper cell tolerance in utero [29, 30].  
HBeAg is a non-particulate secretory protein discovered by Magnius and Espmark in 1972 
[31].  It is derived after cleavage from a 212 amino acid precursor, precore protein that is 
encoded by the HBV precore gene (the pre-C sequence and C-gene). It is highly conserved 
evolutionarily between all Hepadnaviridae. As part of the core protein, it has a nucleic acid 
binding activity [32] required for the pregenomic RNA encapsidation, and modulation of 
polymerase activity for reverse transcription of pregenome [33,34].  
HBeAg is found at concentrations of greater than 10μg mL-1 in the plasma, which can be 
detected even by agar-gel immunodiffusion. Secreted HBeAg has an immunoregulatory 
function in utero by establishing T cell tolerance to HBeAg and HBcAg, which may 
predispose neonates born to HBV-infected mothers to develop persistent HBV infection [29]. 
Milich et al., [35-37] further demonstrated an immunomodulatory role of HBeAg in antigen 
presentation and recognition by CD4+ cells. 
2.4. Hepatitis B X antigen (HBxAg) 
HBx antigen, a 17 kDa multifunctional, non-structural protein, comprised of 154 amino 
acids, which is conserved across all the mammalian infecting Hepadnaviridae. The X gene is 
the smallest of the four partially overlapping ORF of the HBV genome. The biological 
function of HBx protein is not yet clear however this has been implicated in causing HBV 
associated liver cancer.  
Accumulating evidences indicate that the HBV X gene is indispensable to HBV replication, 
propagation and integration of viral DNA into the host’s genome. The expression of full-
length HBx protein is dispensable for virus production in vitro and a critical component of 
the infectivity process in vivo [38]. HBx protein promotes virus gene expression and 
replication by trans-activating the virus promoters and enhancer/promoter complexes [39, 
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40]. In addition, HBx accumulation enhances viral replication by altering various cellular 
activities including aberrant expression of molecules, involved in host cell signal 
transduction, transcription and proliferation, leading to viral persistence and 
hepatocarcinogenesis [41, 42, 43].  
3. HBV viral load 
HBV is reported to be present in the blood of HbeAg seropositive individuals at a 
concentration of approximately 108–109 viral particles mL-1 of blood [44]. HBV DNA is 
present in high titers in blood and exudates of in acute as well as chronic cases.  Generally, 
moderate viral titers are found in saliva, semen and vaginal secretions [45, 46].  The serum 
levels of HBV DNA largely depend on the viral genotype, and the quantity of HBeAg in 
serum, which determines the progression of liver cirrhosis to carcinoma.  
3.1. HBV genotypes and subgenotypes   
The global HBV genome diversity is influenced by both genotypic and phenotypic 
variability; genotypes often evolve in the absence of selective pressure but phenotypic 
variability often develops in the presence of selective pressure exerted by host immune 
system or even during certain therapeutic measures [47].  
This genetic diversity of HBV has been associated with differences in clinical and virological 
characteristics, indicating that they may play a role in the virus–host relationship [48]. 
Genotypes may result from neutral evolutionary drift of the virus genome, from 
recombination, or as a consequence of a long-term adaptation of HBV to genetic 
determinants of specific host populations. Structural and functional differences between 
genotypes can influence the severity, course and likelihood of complications, HBeAg 
seroconversion and response to treatment of HBV infection and possibly the vaccination 
against the virus [49]. 
Traditionally HBV was classified into 4 subtypes or serotypes (adr, adw, ayr, and ayw) 
based on antigenic determinants of HBsAg [50]. In the advent of more molecular 
approaches, serotyping of viral strains was replaced by various genotyping methods. 
Galibert et al. [51], published the first sequence of a complete HBV genome. Later, Okamoto 
et al.  [52], analyzed 18 full length genomes and divided them into four groups or genotypes, 
named as A to D. The ability of HBV to adapt to the host genetics as well as immunogenic 
environment by genetic variation, led to the evolution of eight established genotypes (A-H): 
[8, 53] and two putative genotypes (I and J), each corresponding to a rather well-defined 
geographical distribution (Table 1). HBV genotypes A and D have worldwide distribution, 
whereas genotypes B and C are mostly found in Asia. In India HBV genotypes A and D are 
common in various parts, followed by genotype C specifically in eastern part of India [54-
56]. The new genotype I is a complex recombinant form of genotypes A, C, and G [57,58]. 
The genotype J which was positioned phylogenetically in between the human and ape 
genotypes and was isolated from a 88-year-old hepatitis patient living in Okinawa, Japan 
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who had a history of residing in Borneo during the World War II [59].  In addition, countries 
in which multiple genotypes circulate, co-infections and recombination events may occur 
leading to the emergence of hybrid strains that can become the dominant subgenotype 
prevailing in certain geographical regions. 
 
Table 1. Overview of HBV major genotypes and its distribution pattern 
3.2. HBV Genotyping  
Currently, more than 10 different methods have been developed for HBV genotyping with 
variable sensitivity, specificity, turnaround time and cost. These methods include restriction 
fragment length polymorphisms (RFLP) [60], PCR with specific primers for single genotypes 
[61], multiplex-PCR for many HBV genotypes [62, 63] and on hybridization technologies 
[64] or real time quantification and genotyping [65] or Mass spectrometry [66].  The gold 
standard method for HBV genotyping is a complete genome sequencing followed by 
phylogenetic analysis of the sequence divergence [9, 52]. Sequence and phylogenetic 
analysis can also be performed on individual genes, more often in envelope (S) gene. The 
reliability of using individual genes or limited gene sequence will depend both on the size of 
the sequence analyzed and the degree of sequence homology. The HBV genotype can be 
determined by other methods that are based on a limited number of conserved nucleotide or 
amino acid differences between the genotypes. Line probe assay (LiPA) may be a suitable 
alternative to sequencing but it is expensive when compared to other methods such as 
multiplex PCR, RFLP and serotyping. Based on the sensitivity, other methods such as 
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microarrays, real time PCR, reverse dot blot, restriction fragment mass polymorphism 
(RFMP), invader assay are being used  [67,68]. Identification of HBV genotypes will be 
useful to understand the source of infection, predict clinical outcome at individual level and 
monitoring the development of newer viral strains at population level. 
3.3. Clinical implications of HBV genotyping 
Mounting evidence shows that HBeAg seroconversion rates, HBcAg seroconversion, 
viremia levels, viral latency, immune escape, emergence of mutants, pathogenesis of liver 
disease, response and resistance to antiviral therapy are all depend on the HBV genotypes 
and subgenotypes. Individual or combinations of the above factors are responsible for the 
degree of clinical heterogeneity displayed by the infected persons [69, 70].  
Earlier reports from India, where genotypes A, D are prevalent and patients infected with 
genotype D had relatively high degree of disease severity and develop HCC [56]. Patients 
with genotypes C and D have a lower response rate to interferon therapy than patients 
infected with genotypes A or B [71,72]. An Alaskan population study which compares the 
clinical virological properties of five genotypes has shown that the mean age seroconversion 
from HBeAg to anti-HBe is significantly lower among genotypes A, B, D and F, than 
compared to genotype C [73]. This may be due to the development of more mutations in the 
basal core promoter region of genotypes C and D compared to genotypes A and B. 
Genotype G appears defective, and usually occurs together with another genotype, which 
provides transcription factors necessary for replication. Viral load of the patients with 
genotype mixture is usually higher than that of those infected with unique genotype.  
3.4. HBV mutant (Phenotypic variants) 
Phenotypic variants emerge in response to selective pressure [47]. Development of HBV 
mutants are often related to the persistence of cccDNA and viral factors such as the 
existence of quasispecies, high rate of HBV replication, error prone RT-based life cycle and 
adaptive mutants with compensatory mutations. Host factors include compliance with 
antiviral therapy, immune response, enhanced hepatic inflammatory response and host 
genetic background. HBV quasispecies arise due to the average daily production of >1011 
virions with a error rate of 1.4-3.2 x 10-5 nucleotide substitutions per site per year, which 
results in production of all possible number of different single base changes in the HBV 
genome [74-76]. Active replication leads to an estimated misincorporation rate of around 104 
owing to the lack of proof-reading (3’ – 5’ exonuclease activity) [77]. The combination of a 
high error rate together with an increased replication rate produces as high as 109 mutation 
day-1 over the entire 3.2kb genome [74, 78] but, the extreme overlapping of the ORF of the 
HBV genome limits the possibility of all these mutations [79]. 
Moreover, mutations in the HBV genome seem to play a vital role in differential outcome of 
this infection (Table 2). Two important mutations in the HBV virus have been associated 
with differential outcome such as the basal core promoter (BCP) mutation and the pre-core 
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(PC) mutation. BCP mutation is a double substitution, A1762T, G1764A, in the basal core 
region of HBV. It has clearly been associated with an increased risk of HCC and cirrhosis in 
multiple studies, both cross-sectional and prospective [80]. 
Table 2. HBV mutants and its clinical impact 
4. Treatment 
Antiviral medications for the management of chronic HBV infections currently available 
include alpha interferon (IFN-α) and three nucleoside analogs: lamivudine, adefovir and 
entecavir that inhibit viral nucleocapsid formation and block viral DNA synthesis by 
premature chain termination [81,82]. The major determinant involved in the selection of 
drug-resistant mutation is the fitness of the mutants and the replication space available for 
the spread of mutants. In chronic hepatitis B, the replication space is provided by hepatocyte 
turnover, which allows the loss of HBV wild-type infected cells and the generation of non-
infected hepatocytes that are susceptible to new HBV mutant infections. Long-term therapy 
of adefovir or entecavir mediates significant reduction in cccDNA, but still fails to eliminate 
chronic HBV infections [83, 84]. 
5. Conclusion 
Among all forms of viral hepatitis, HBV infection is considered as a major infectious disease 
due to the broad range of clinical spectrum and the progressive complications displayed by 
the infected individuals. Avians, rodents and human forms of the virus have been 
recognized for many years and infections were assumed to be highly host specific. The 
geographic pattern of HBV genotype distribution is not only influenced by the host and 
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viral factors but also by socio-economical factors like migration and immigration of people, 
availability of vaccine and anti-viral therapeutics. The genetic diversity of HBV has been 
associated with clinical outcome, and response to antiviral therapy. Various forces like 
natural selection pressure, antiviral drug mediated pressure and error prone high 
replication rate are the important factors responsible for this genetic diversity. The final 
outcome from this infectious disease is solely determined by specific interaction between 
viral components and immunogenetics of the host. Understanding the influence and the role 
of viral genetic diversity is considered as a prerequisite to better the treatment options. 
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